C
아이엠바이오로직스
493280KOSDAQ자연과학 및 공학 연구개발업44.5 / 100
Reference Date: 2026-07-24
Financial Score19.0 / 40
News Sentiment12.5 / 25
Momentum3.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Plunged 21.9% over the past month, and news sentiment is neutral.
Company InformationBased on 2025 Annual Report
Number of Employees
41people
Average Salary
76.2M KRW
Score Calculation Basis
Detailed Financial Score
PER
139.77Industry Average 43.640.0Point
3.2x industry avg (risky)
PBR
3.61Industry Average 2.522.5Point
Higher than industry avg (caution)
ROE
—Industry Average -32.093.5Point
Debt Ratio
1.09Industry Average 7.318.0Point
Half of industry avg (excellent)
Trend 5.0 / 10 points
Revenue Growth Rate
1.5 / 3
Operating Profit Growth Rate
1.5 / 3
ROE Trend
2.0 / 4
Detailed News Sentiment
5 totalPositive 0Neutral 5Negative 0Average Sentiment Score 50
- Neutral[증권사 IPO 재편]④ 신한證, 스팩으로 상반기 실적 '방어'
신한투자증권의 상반기 IPO 실적은 시장 상황에 따라 방어적 성격이 강했으나, 아이엠바이오로직스와 직접적인 연관성이 없다.
- Neutral공모가 무너진 바이오 새내기들…하반기 모멘텀이 반등 계기될까
바이오 새내기들의 공모가 하락에도 불구하고, 하반기 모멘텀에 대한 기대감이 주목받고 있다.
- Neutral제약·바이오 IPO, 투심회복이냐 옥석가리기냐
IPO market shows qualitative improvements despite fewer listings compared to last year.
Detailed Momentum
52-week position1.0Point
Near 52w low (1%, downtrend)
Current 17,890Won52-week high 104,00052-week low 16,300
1-month return0.0Point
1m -21.88% (strong drop)
Volume trend2.0Point
Volume decreasing
Detailed Disclosure
0 totalPositive 0Neutral 0Negative 0